The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

About 90% of U.S. adults meet the criteria for a newly recognized syndrome that comes from a combination of heart disease, ...

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Can telemedicine and exercise apps improve the health of people with type 2 diabetes and coronary heart disease? A large ...

Driven by rising rates of high blood pressure, obesity, and other key risk factors, heart disease remains the leading cause ...

The deaths are also partly the result of medical successes: People are living longer, and more people are surviving heart ...

Nerve damage: Diabetes can damage nerves responsible for the heart and blood vessels, affecting the heart's rhythm and the ...

About 90% of U.S. adults meet the criteria for a newly recognized syndrome that comes from a combination of heart disease, kidney disease, type 2 diabetes and obesity.[1] This cluster of chronic ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...